Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription 06.07.2026 4 Am J Hematol 14 Ann Hematol 4 Blood 4 BMC Cancer 2 Bone Marrow Transplant 1 Cancer Chemother Pharmacol 6 Eur J Haematol 1 Exp Cell Res 1 Gene 1 Int J Hematol 1 J Pediatr Hematol Oncol 1 J Virol 1 Leuk Lymphoma 1 Leuk Res 6 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. HOFF FW, Zeidner JF, Torlapati G, Nicolet D, et al
   Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
   Am J Hematol. 2026 Jul 2. doi: 10.1002/ajh.70419.
   PubMed         Abstract available
   
   
2. BERNAL T, Zambrano Marquez J, Rodriguez-Veiga R, Rodriguez-Arboli E, et al
   Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.
   Am J Hematol. 2026 Jun 29. doi: 10.1002/ajh.70424.
   PubMed         Abstract available
   
   
3. PAN J, Fu C, Ling Q, Lu Y, et al
   Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.
   Am J Hematol. 2026;101:1938-1953.
   PubMed         Abstract available
   
   
4. ZHAO H, Lin Z, Zheng H, Wei G, et al
   Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up.
   Am J Hematol. 2026;101:1866-1877.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. SUN HL, Zhao ZF, Yin XY, Lv M, et al
   Blinatumomab exposure prior to allogeneic stem cell transplantation is associated with increased Epstein-Barr virus reactivation.
   Ann Hematol. 2026;105:43.
   PubMed         Abstract available
   
   
6. FENG G, Li Y, Wang Y, Li Y, et al
   Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway.
   Ann Hematol. 2026;105:107.
   PubMed         Abstract available
   
   
7. PERRONE S, Corbingi A, Vetro C, Palumbo FE, et al
   Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.
   Ann Hematol. 2026;105:110.
   PubMed         Abstract available
   
   
8. KAWANO M, Kunimoto H, Izumi A, Adachi A, et al
   Successful treatment of relapsed FLT3-mutated donor cell-derived MDS/AML with FLT3 inhibitor gilteritinib.
   Ann Hematol. 2026;105:134.
   PubMed         Abstract available
   
   
9. ZABLONSKI KG, Sabir U, Mendler JH, Alexis JD, et al
   Successful allogeneic stem cell transplant in a patient with a left ventricular assist device: a novel case report.
   Ann Hematol. 2026;105:171.
   PubMed         Abstract available
   
   
10. MAO X, Shen K, Wang J, Wang Z, et al
    TET2 germline mutation in a patient with sequential lymphoid malignancies: a novel case report.
    Ann Hematol. 2026;105:184.
    PubMed         Abstract available
    
    
11. JOVEIN MM, Meyer T, Waterhouse M, Pfeifer D, et al
    Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.
    Ann Hematol. 2026;105:213.
    PubMed         Abstract available
    
    
12. BRUZZESE A, Lofaro D, Martino EA, Mendicino F, et al
    Comparative efficacy of different therapeutic approaches in treatment naive FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials.
    Ann Hematol. 2026;105:226.
    PubMed         Abstract available
    
    
13. MURATORE E, Giunchi V, Fusaroli M, Baccelli F, et al
    Neutropenia and infectious events during off-label treatment with venetoclax in children with malignant disease: a pharmacovigilance analysis of FDA adverse event reporting system reports.
    Ann Hematol. 2026;105:264.
    PubMed         Abstract available
    
    
14. JIANG B, Zhu Y, Jiang Y, Huang J, et al
    Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph(-) BCP-ALL: A retrospective study.
    Ann Hematol. 2026;105:271.
    PubMed         Abstract available
    
    
15. WANG K, Li X, Li X, Yuan X, et al
    Safety and efficacy of chidamide for maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with T-ALL/T-LBL.
    Ann Hematol. 2026;105:306.
    PubMed         Abstract available
    
    
16. SUGIURA H, Asada N, Asano T, Hiramatsu Y, et al
    WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy.
    Ann Hematol. 2026;105:309.
    PubMed         Abstract available
    
    
17. JOSHI U, Zahra FT, Patel P, Al Ali N, et al
    Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).
    Ann Hematol. 2026 Jul 2. doi: 10.1007/s00277-026-07145.
    PubMed         Abstract available
    
    
18. KOUMPIS E, Minga E, Talimtzi P, Angelopoulou M, et al
    Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.
    Ann Hematol. 2026 Jul 3. doi: 10.1007/s00277-026-07161.
    PubMed         Abstract available
    
    

    
    Blood

19. 
    Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013-3022.
    Blood. 2026;148:146.
    PubMed        
    
    
20. LEI Y, Lai Y, Li Y, Wang Y, et al
    Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming.
    Blood. 2026 Jun 30:blood.2025032710. doi: 10.1182/blood.2025032710.
    PubMed         Abstract available
    
    
21. MEYERHOFER M, Zhou Y, Gallego-Crespo A, Shah V, et al
    Inhibition of p300/CREBBP catalytic activity drives context-dependent transcriptional activation in AML.
    Blood. 2026;148:84-102.
    PubMed         Abstract available
    
    
22. GAO L, Zhai X, Wang N, Liao N, et al
    Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial.
    Blood. 2026;148:71-83.
    PubMed         Abstract available
    
    

    
    BMC Cancer

23. LEHMANN J, Bohn JP, Seidl C, Vorbach SM, et al
    Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.
    BMC Cancer. 2025;25:1664.
    PubMed         Abstract available
    
    
24. WANG JF, Cheng J
    The prognostic value of maintaining minimal residual disease status in patients with acute myeloid leukaemia receiving azacitidine-based therapy.
    BMC Cancer. 2026;26:592.
    PubMed         Abstract available
    
    
25. GHAZVINI ZADEGAN F, Stanko C, Fiedler F, Olsner L, et al
    Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression.
    BMC Cancer. 2026;26:777.
    PubMed         Abstract available
    
    
26. WANG J, Wang S, Xu F, Hu H, et al
    Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic.
    BMC Cancer. 2026 Jul 1. doi: 10.1186/s12885-026-16437.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

27. SPYRIDONIDIS A, Ferhat AT, Galimard JE, Schroeder T, et al
    A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.
    Bone Marrow Transplant. 2026 Jul 2. doi: 10.1038/s41409-026-02950.
    PubMed         Abstract available
    
    
28. KAYSER S, Nagler A, Ferhat AT, Sanz J, et al
    T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/E
    Bone Marrow Transplant. 2026 Jun 27. doi: 10.1038/s41409-026-02951.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

29. LE TV, Dunn A, Holleran JL, Marino C, et al
    Pharmacokinetics of venetoclax in a patient after whipple pancreaticoduodenectomy.
    Cancer Chemother Pharmacol. 2026;96:42.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

30. MAY M, Limon De la Rosa N, Duarte C, Boosma G, et al
    Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic Leukemia.
    Eur J Haematol. 2026 Jun 29. doi: 10.1111/ejh.70251.
    PubMed        
    
    
31. KENNEDY VE, Peretz CAC, Koh A, Tran E, et al
    Multiomic Single-Cell Sequencing Identifies BCR::ABL1 as an Acquired Resistance Mechanism in FLT3+ AML.
    Eur J Haematol. 2026;117:501-503.
    PubMed         Abstract available
    
    
32. MARTINO EA, Chiarenza A, Mancuso S, Rossi M, et al
    Regional Standardization of CLL Management: Results of a Delphi Consensus Process.
    Eur J Haematol. 2026;117:442-447.
    PubMed         Abstract available
    
    
33. MARTINO EA, Caserta S, Vigna E, Bruzzese A, et al
    From Time-Limited Therapy to Treatment-Free Observation: The Evolving Role of MRD in CLL Management.
    Eur J Haematol. 2026;117:305-319.
    PubMed         Abstract available
    
    
34. KUTSCH N, Ligtvoet R, Robrecht S, Linde H, et al
    Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.
    Eur J Haematol. 2026;117:351-357.
    PubMed         Abstract available
    
    
35. MOLICA S, Lucignano M, Villa MR, Mettivier L, et al
    Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks.
    Eur J Haematol. 2026;117:366-374.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

36. TIMOSHENKO AV, Kay SC
    Neutrophilic differentiation of promyelocytic HL-60?cells is associated with increased expression of terminal galactose residues on the cell surface.
    Exp Cell Res. 2026;461:115107.
    PubMed         Abstract available
    
    

    
    Gene

37. LIU AQ, Shao YL, Wang KT, Wang N, et al
    Reduced ATXN1 expression as an adverse prognostic indicator in Acute myeloid leukemia.
    Gene. 2026 Jul 1:150295. doi: 10.1016/j.gene.2026.150295.
    PubMed         Abstract available
    
    

    
    Int J Hematol

38. TAKAHASHI N, Kimura S, Matsuki E, Ono T, et al
    Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.
    Int J Hematol. 2026;124:96-103.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

39. ABDELGAWAD HAH, Hinkle K, Fodor B, Ritchey A, et al
    Assessment of Immunization Status Following Non-HSCT Chemotherapy-treated Pediatric Leukemia Survivors.
    J Pediatr Hematol Oncol. 2026 Jun 29. doi: 10.1097/MPH.0000000000003230.
    PubMed         Abstract available
    
    

    
    J Virol

40. XIN X, Mao Y, Li Q, Wang X, et al
    HTLV-1 Tax and HBZ cooperatively promote leukemogenesis through miR-155-mediated PTEN suppression and PI3K-Akt activation.
    J Virol. 2026;100:e0055426.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

41. GAO B, Yan W, Xue J, Zhang S, et al
    MBP1 inhibits AML proliferation through downregulating noncanonical Wnt/Ca(2+) signaling pathway.
    Leuk Lymphoma. 2026;67:1749-1759.
    PubMed         Abstract available
    
    

    
    Leuk Res

42. MATSUKAWA T, Nagai J, Kanaya M, Hashiguchi J, et al
    A multicenter real-world study of clinical outcomes in octogenarians and older patients with acute myeloid leukemia.
    Leuk Res. 2026;168:108269.
    PubMed         Abstract available
    
    

    
    Leukemia

43. ZHANG M, Liu L, Fu S, Feng J, et al
    CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.
    Leukemia. 2026 Jul 3. doi: 10.1038/s41375-026-03017.
    PubMed         Abstract available
    
    
44. WINKLER R, Griesler B, Sippl W, Boon RA, et al
    Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.
    Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03040.
    PubMed         Abstract available
    
    
45. TRABER GM, Mark K, Jayanthan A, Chae HD, et al
    Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.
    Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03034.
    PubMed        
    
    
46. GARCIA C, Lyons KU, Contreras JG, Liu T, et al
    FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03030.
    PubMed         Abstract available
    
    
47. AYYADEVARA VSSA, Perencsik R, Patil S, Gaur S, et al
    Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.
    Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03011.
    PubMed        
    
    
48. WANG Y, Xin Z
    Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities.
    Leukemia. 2026 Jun 30. doi: 10.1038/s41375-026-03039.
    PubMed        
    
    

    
    PLoS One

49. JEVIC F, Andel R, Kraus J, Kobesova A, et al
    Electrophysiological asymmetry in vincristine-exposed children with acute lymphoblastic leukemia: Evidence from bilateral nerve conduction studies.
    PLoS One. 2026;21:e0352440.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum